0
Letters |

Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease—Reply

Stefan D. Anker, MD, PhD; Stephan von Haehling, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4178.
Text Size: A A A
Published online

Extract

In Reply: We agree with Dr Slatopolsky that many aspects merit attention in the discussion of paricalcitol. We also agree that paricalcitol is effective and even faster than 1,25-hydroxyvitamin D3 in the suppression of elevated levels of parathyroid hormone.1 This is also the case in patients with significantly elevated levels of phosphorus, a subgroup of patients usually deemed resistant to 1,25-hydroxyvitamin D3.2 However, in the space of an editorial, we were not able to provide a complete overview of paricalcitol and therefore primarily focused on summarizing the evidence in the field of CKD and left ventricular hypertrophy, which was the area of concern for the PRIMO trial. No beneficial effects of paricalcitol have yet been demonstrated in this regard.

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

June 6, 2012
Costas Fourtounas, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4168.
June 6, 2012
Sanjay Rajagopalan, MD; Christopher T. Chan, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4170.
June 6, 2012
Ravi Thadhani, MD, MPH; Hector Tamez, MD, MPH; Scott D. Solomon, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4176.
June 6, 2012
Eduardo Slatopolsky, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4172.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();